Indivior's SUBLOCADE Shows Up to 8x Relapse Reduction, Lower Healthcare Use in New Studies
INDV has more than doubled off its 52-week low of $11.065.
Summary
Indivior announced new real-world evidence studies demonstrating significant benefits for its monthly injectable buprenorphine, SUBLOCADE. The studies show that adherence to SUBLOCADE is associated with a 3.5 to 8.1 times lower likelihood of opioid relapse, a 62% reduction in bacteremia incidence, and substantial decreases in overall healthcare utilization, including 56% fewer inpatient visits. These strong clinical findings for a core product are material for Indivior, as they can bolster SUBLOCADE's market position, support sales growth, and potentially influence payer coverage and clinical guidelines. Traders will watch for how these data translate into increased adoption and revenue for the company.
At the time of this announcement, INDV was trading at $37.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.5B. The 52-week trading range was $11.07 to $41.00. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.